Eli Lilly and Company (NYSE:LLY) Shares Bought by Simmons Bank

Simmons Bank raised its position in Eli Lilly and Company (NYSE:LLY) by 1.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 8,409 shares of the company’s stock after acquiring an additional 121 shares during the period. Simmons Bank’s holdings in Eli Lilly and Company were worth $7,450,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Haverford Trust Co lifted its stake in shares of Eli Lilly and Company by 0.9% in the third quarter. Haverford Trust Co now owns 3,515 shares of the company’s stock valued at $3,114,000 after purchasing an additional 31 shares during the period. Empower Advisory Group LLC lifted its position in shares of Eli Lilly and Company by 4.3% during the 3rd quarter. Empower Advisory Group LLC now owns 139,274 shares of the company’s stock valued at $123,388,000 after acquiring an additional 5,682 shares during the period. Moser Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 40.0% during the 3rd quarter. Moser Wealth Advisors LLC now owns 455 shares of the company’s stock worth $403,000 after acquiring an additional 130 shares in the last quarter. Carrera Capital Advisors acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $244,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 0.3% in the 3rd quarter. Victory Capital Management Inc. now owns 697,335 shares of the company’s stock worth $617,797,000 after acquiring an additional 1,961 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.6 %

Shares of LLY stock opened at $818.79 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a 50-day simple moving average of $891.02 and a 200 day simple moving average of $870.71. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The stock has a market capitalization of $777.29 billion, a P/E ratio of 88.52, a P/E/G ratio of 3.15 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 earnings per share. On average, sell-side analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is presently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Finally, Guggenheim increased their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,008.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.